WO2008071667A1 - Nutritional composition - Google Patents
Nutritional composition Download PDFInfo
- Publication number
- WO2008071667A1 WO2008071667A1 PCT/EP2007/063622 EP2007063622W WO2008071667A1 WO 2008071667 A1 WO2008071667 A1 WO 2008071667A1 EP 2007063622 W EP2007063622 W EP 2007063622W WO 2008071667 A1 WO2008071667 A1 WO 2008071667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- nutritional composition
- source
- kcal
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to a nutritional composition, more specifically to a nutritional composition designed for infants deemed to be at risk of developing obesity later in life.
- BMI body mass index
- the present invention provides a nutritional composition for infants at risk of developing obesity later in life comprising a protein source, a lipid source and a carbohydrate source and having a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.
- the invention also extends to the use of a protein source, a lipid source and a carbohydrate source for the preparation of a nutritional composition having a protein content of less than 1.8g/l 00 kcal and an energy density of less than 650 kcal/litre for administration to an infant at risk of developing obesity later in life in the first year of life of the infant so as to reduce that risk.
- the invention further extends to a method of reducing the possibility that an infant at risk of developing obesity later in life will develop obesity comprising feeding to the at risk infant in the first year of its life a nutritional composition comprising a protein source, a lipid source and a carbohydrate source and having a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.
- At least 20% by weight of the protein source is casein, more preferably at least 30%.
- the ratio of linoleic acid (C18:2n-6): ⁇ -linolenic acid (C18:3n-3) in the lipid source is less than 7: 1.
- the ratio of arachidonic acid (C20:4n- 6):docosahexaenoic acid (C22:6n-3) in the lipid source is preferably between 2:1 and
- infant means a child under the age of 12 months
- infant at risk of developing obesity later in life means an infant born to an obese mother
- protein content means total content of proteinaceous material including free amino acids (if present).
- references to the energy density of the nutritional composition in a specified number of kilocalories per litre refer, in the context of powdered products, to the product after re- constitution according to the directions provided with the product.
- the energy density of a nutritional composition according to the invention is less than 650 kcal/1, preferably between 620 and 640 kcal/1.
- the nutritional composition of the present invention has a protein content of less than 1.8 g/100 kcal.
- the protein content is between 1.4 and 1.7 g/100 kcal.
- the detailed make-up of the protein source is not believed to be critical to the present invention provided that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
- protein sources based on cows' milk proteins such as whey, casein and mixtures thereof may be used as well as protein sources based on soy.
- mixtures of whey and casein proteins are preferred.
- the casein:whey ratio may lie in the range from 70:30 to 30:70 but is preferably 40:60.
- the protein(s) in the protein source may be intact or partially hydrolysed or a mixture of intact and hydrolysed proteins may be used. However, intact proteins are preferred.
- the protein source may additionally be supplemented with free amino acids if this is necessary to meet the minimum requirements for essential amino acid content. These requirements are published for example in EC Directive 91/321 /EEC. However, it will be appreciated that because of the over-riding need to control the protein content of the nutritional composition as discussed above, supplementation with free amino acids may be driven primarily by the amino acid profile of the protein source(s) selected and the resultant need to supplement with certain free amino acids if any. This is illustrated further in the examples below.
- the preferred protein source is a mixture of casein and whey proteins.
- the whey protein may be a whey protein isolate, acid whey, sweet whey or sweet whey from which the caseino-glycomacropeptide has been removed (modified sweet whey).
- the whey protein is modified sweet whey.
- Sweet whey is a readily available by-product of cheese making and is frequently used in the manufacture of nutritional compositions based on cows' milk.
- sweet whey includes a component which is undesirably rich in threonine and poor in tryptophan called caseino- glycomacropeptide (CGMP). Removal of the CGMP from sweet whey results in a protein with a threonine content closer to that of human milk.
- a process for removing CGMP from sweet whey is described in EP 880902.
- modified sweet whey is used as the whey protein in a mixture of 60% whey and 40% casein
- the protein source is preferably supplemented by free tryptophan, isoleucine, histidine and phenylalanine in amounts of up to 0.34% for tryptophan, 0.92% for isoleucine, 0.19% for histidine and 2.2% for phenylalanine (in each case as a percentage by weight of total protein content).
- the protein source is preferably supplemented by free tryptophan, leucine, histidine and phenylalanine in amounts of up to 0.5% for tryptophan, 0.37% for leucine, 0.3% for histidine and 2.5% for phenylalanine (in each case as a percentage by weight of total protein content).
- the nutritional compositions of the present invention contains a source of carbohydrates.
- the preferred source of carbohydrates is lactose although other carbohydrates such as saccharose, maltodextrin, and starch may also be added.
- the carbohydrate content of the nutritional composition is between 9 and 14 g/100 kcal.
- the nutritional composition of the present invention contains a source of lipids.
- the lipid source may be any lipid or fat which is suitable for use in nutritional compositions to be fed to infants.
- Preferred fat sources include coconut oil, low erucic rapeseed oil (canola oil), soy lecithin, palm olein, and sunflower oil.
- the essential polyunsaturated fatty acids linoleic acid and ⁇ -linolenic acid will also be added as may small amounts of oils containing high quantities of preformed long chain polyunsaturated fatty acids arachidonic acid and docosahexaenoic acid such as fish oils or single cell oils.
- the lipid content may be between 4.4 and 6 g/100 kcal.
- the ratio of linoleic acid (C 18:2n-6): ⁇ -linolenic acid (C18:3n-3)in the lipid source is less than 7:1, more preferably between 7:1 and 5:1.
- the ratio of arachidonic acid (C20:4n- 6):docosahexaenoic acid (C22:6n-3) in the lipid source is preferably between 2:1 and
- the nutritional composition may also contain all vitamins and minerals understood to be essential in the daily diet in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the nutritional composition include vitamin A, vitamin Bi, vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form.
- the nutritional composition may contain emulsif ⁇ ers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like. This is especially the case if the composition is provided in liquid form.
- the nutritional composition may optionally contain other substances which may have a beneficial effect such as probiotic bacteria, fibres, lactoferrin, nucleotides, nucleosides, and the like in the amounts customarily found in nutritional compositions to be fed to infants.
- the nutritional composition may be prepared in any suitable manner.
- a nutritional composition may be prepared by blending together the protein source, the carbohydrate source, and the lipid source in appropriate proportions. If used, emulsif ⁇ ers may be included in the blend at this stage. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
- the liquid mixture may then be thermally treated to reduce bacterial loads.
- the liquid mixture may be rapidly heated to a temperature in the range of about 80 0 C to about 110 0 C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
- the liquid mixture may then be cooled to about 60 0 C to about 85°C; for example by flash cooling.
- the liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage.
- the homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added.
- the pH and solids content of the homogenised mixture is conveniently standardised at this point.
- the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- the powder should have a moisture content of less than about 5% by weight.
- the homogenised mixture is filled into suitable containers; preferably aseptically.
- the liquid composition may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available.
- the liquid composition may be in the form of a ready to feed composition having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
- composition of a nutritional composition according to the invention is given below:
- a nutritional composition according to the invention may be fed to an infant at risk of developing obesity later in life as the sole source of nutrition from the age of three months and subsequently as part of a mixed diet during the introduction of solid foods until weaning is complete at about the age of 12 months.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07857342A EP2096941B1 (en) | 2006-12-15 | 2007-12-10 | Nutritional composition for infants |
| PL07857342T PL2096941T3 (en) | 2006-12-15 | 2007-12-10 | Nutritional composition for infants |
| ES07857342T ES2379737T3 (en) | 2006-12-15 | 2007-12-10 | Nutritive composition for babies |
| BRPI0721087-6A BRPI0721087A2 (en) | 2006-12-15 | 2007-12-10 | NUTRITIONAL COMPOSITION |
| AT07857342T ATE543395T1 (en) | 2006-12-15 | 2007-12-10 | NUTRITIONAL COMPOSITION FOR INFANTS |
| US12/519,043 US9943097B2 (en) | 2006-12-15 | 2007-12-10 | Nutritional composition |
| MX2009006086A MX2009006086A (en) | 2006-12-15 | 2007-12-10 | Nutritional composition. |
| AU2007331578A AU2007331578B2 (en) | 2006-12-15 | 2007-12-10 | Nutritional composition |
| CA002671988A CA2671988A1 (en) | 2006-12-15 | 2007-12-10 | Nutritional composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126282.0 | 2006-12-15 | ||
| EP06126282A EP1932437A1 (en) | 2006-12-15 | 2006-12-15 | Infant formula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008071667A1 true WO2008071667A1 (en) | 2008-06-19 |
Family
ID=37907402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2007/063622 Ceased WO2008071667A1 (en) | 2006-12-15 | 2007-12-10 | Nutritional composition |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9943097B2 (en) |
| EP (2) | EP1932437A1 (en) |
| CN (1) | CN101573049A (en) |
| AT (1) | ATE543395T1 (en) |
| AU (1) | AU2007331578B2 (en) |
| BR (1) | BRPI0721087A2 (en) |
| CA (1) | CA2671988A1 (en) |
| CL (1) | CL2007003650A1 (en) |
| ES (1) | ES2379737T3 (en) |
| MX (1) | MX2009006086A (en) |
| MY (1) | MY158502A (en) |
| PL (1) | PL2096941T3 (en) |
| PT (1) | PT2096941E (en) |
| RU (1) | RU2455857C2 (en) |
| TW (1) | TW200845917A (en) |
| UA (1) | UA96781C2 (en) |
| WO (1) | WO2008071667A1 (en) |
| ZA (1) | ZA200904918B (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010070613A2 (en) | 2008-12-18 | 2010-06-24 | University College London | Baby feeding formula and system |
| WO2010112429A1 (en) * | 2009-04-01 | 2010-10-07 | Nestec S.A. | Reduction of risk of obesity |
| EP2277395A1 (en) * | 2009-07-23 | 2011-01-26 | Opus Ingredients B.V. | Composition, method for producing it and use thereof |
| US7998501B2 (en) | 2003-02-10 | 2011-08-16 | University College London | Newborn infant formulas and feeding methods |
| EP2583562A1 (en) | 2011-10-21 | 2013-04-24 | Nestec S.A. | Use of whey protein micelles for infants at risk of obesity or diabetes |
| US8815279B2 (en) | 2003-02-10 | 2014-08-26 | University College London | Baby feeding formula and system |
| WO2015078938A1 (en) | 2013-11-29 | 2015-06-04 | Nestec S.A. | Age-tailored nutritional compositions with a varying protein content |
| US9474766B2 (en) | 2011-12-27 | 2016-10-25 | Abbott Laboratories | Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life |
| WO2017064309A1 (en) | 2015-10-15 | 2017-04-20 | N.V. Nutricia | Infant formula with milk fat for promoting healthy growth |
| WO2017064304A1 (en) | 2015-10-15 | 2017-04-20 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| WO2017194607A1 (en) | 2016-05-10 | 2017-11-16 | N.V. Nutricia | Fermented infant formula |
| WO2017194615A1 (en) | 2016-05-10 | 2017-11-16 | N.V. Nutricia | Fermented infant formula |
| EP3082463B1 (en) | 2013-11-29 | 2019-05-01 | Nestec S.A. | Use of nutritional compositions having a low protein amount |
| US10548869B2 (en) | 2010-03-17 | 2020-02-04 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes |
| EP3442358B1 (en) | 2016-04-11 | 2021-02-17 | Société des Produits Nestlé S.A. | Infant nutrition delivering metabolic benefits |
| US11109603B2 (en) | 2011-06-20 | 2021-09-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
| US11376222B2 (en) | 2013-11-01 | 2022-07-05 | N.V. Nutricia | Lipid composition for improving body composition during catch-up growth |
| US11632974B2 (en) | 2016-12-09 | 2023-04-25 | N.V. Nutricia | Nutritional composition for improving cell membranes |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2452574A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Age-tailored nutritional formula with particularly adapted caloric density for young infants |
| US9462821B2 (en) | 2008-12-08 | 2016-10-11 | Nestec S.A. | Modulation of infant fat mass |
| CA2749254A1 (en) | 2009-01-19 | 2010-07-22 | Catherine Mace | Nutritional composition for infants |
| MX2011010454A (en) * | 2009-04-03 | 2012-01-25 | Nestec Sa | Improvement in promotion of healthy catch-up growth. |
| EP2404507A1 (en) * | 2010-07-08 | 2012-01-11 | Nestec S.A. | Array of age-tailored nutritional formula with optimum fat content |
| WO2012044155A1 (en) * | 2010-09-28 | 2012-04-05 | N.V. Nutricia | Fat composition for programming immune response |
| EP2452573A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Age-tailored nutritional composition with animal fats and vegetable fats |
| WO2012092082A1 (en) * | 2010-12-30 | 2012-07-05 | Abbott Laboratories | Reduced buffering capacity of a low calorie infant formula |
| NZ612099A (en) * | 2010-12-30 | 2015-02-27 | Abbott Lab | Low calorie infant formula with improved physical attributes |
| MX2013007694A (en) * | 2010-12-30 | 2013-08-15 | Abbott Lab | Improved tolerance in a low calorie infant formula. |
| WO2012092083A1 (en) * | 2010-12-30 | 2012-07-05 | Abbott Laboratories | Improved rate of protein digestion in a low calorie infant formula |
| EP2514435A1 (en) | 2011-04-19 | 2012-10-24 | Nestec S.A. | Infant formula for use in the prevention of cardiovascular diseases |
| CN104302192A (en) * | 2011-12-27 | 2015-01-21 | 雅培制药有限公司 | Reduced calorie infant formulas containing specific whey to casein ratios |
| RU2670883C2 (en) * | 2012-03-12 | 2018-10-25 | Н.В. Нютрисиа | Process for the humanization of animal skim milk and products obtained thereby |
| SE536599C3 (en) | 2012-04-10 | 2017-01-10 | Hero Ag | Nutritional composition with low calorie and low protein content |
| US20140170259A1 (en) * | 2012-12-14 | 2014-06-19 | Mead Johnson Nutrition Company | Nutritional composition for promoting satiety |
| WO2015041515A1 (en) * | 2013-09-19 | 2015-03-26 | N.V. Nutricia | Improved process for the humanization of animal skim milk |
| WO2015078939A1 (en) * | 2013-11-29 | 2015-06-04 | Nestec S.A. | Devices, systems and methods of assessing the risk of obesity later in life of an infant or a young child |
| EP3082472A1 (en) * | 2013-11-29 | 2016-10-26 | Nestec S.A. | Infant nutrition for improvement in insulin sensitivity later in life |
| AU2014361229A1 (en) | 2013-12-12 | 2016-04-28 | Nestec S.A. | Synthetic nutritional compositions especially adapted for male and female infants and young children |
| WO2015095570A2 (en) * | 2013-12-19 | 2015-06-25 | Abbott Laboratories | Nutritional composition comprising hydrolyzed protein |
| BR112016014700B1 (en) * | 2014-01-10 | 2020-11-10 | Société Des Produits Nestlé S.A | uses of vitamin b6, and maternal food composition |
| CN114469959A (en) * | 2014-03-21 | 2022-05-13 | 雀巢产品有限公司 | Administering vitamin B2 to mothers prevents increased offspring obesity, overweight or obesity |
| WO2015178762A1 (en) * | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Enteral formulations for preterm infants comprising optimised phenylalanine intake levels |
| WO2015178761A1 (en) * | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Formulas comprising optimised amino acid profiles |
| US10188135B2 (en) * | 2015-11-04 | 2019-01-29 | Stokley-Van Camp, Inc. | Method for inducing satiety |
| JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
| JOP20200033A1 (en) | 2017-08-14 | 2020-02-13 | Axcella Health Inc | Amino acid compositions for the treatment of liver disease |
| WO2019246225A1 (en) | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| WO2021110916A1 (en) * | 2019-12-05 | 2021-06-10 | N.V. Nutricia | Infant formula with special lipid architecture for improving postnatal growth of infants born to overweight and obese mothers |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124237A1 (en) * | 2001-12-21 | 2003-07-03 | Wyeth | Infant formula compositions comprising increased amounts of alpha-lactalbumin |
| WO2004112508A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
| WO2006057551A1 (en) * | 2004-11-26 | 2006-06-01 | N.V. Nutricia | Infant nutrition with protease inhibitor |
| WO2006069918A1 (en) * | 2004-12-27 | 2006-07-06 | Nestec S.A. | Use of infant formula with reduced protein content |
| WO2007004878A2 (en) * | 2005-07-01 | 2007-01-11 | N.V. Nutricia | Infant nutrition with hydrolised proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0880902A1 (en) | 1997-05-27 | 1998-12-02 | Nestlé Produkte AG | Process for treating a raw whey material |
| EP0951842B1 (en) * | 1999-01-20 | 2002-12-04 | N.V. Nutricia | Infant formula |
| GB9923048D0 (en) * | 1999-09-29 | 1999-12-01 | Nestle Sa | Composition comprising casein protein and whey protein |
| BRPI0407220A (en) * | 2003-02-10 | 2006-01-31 | Univ London | Baby Feeding Formula and Baby Feeding Formula Container |
-
2006
- 2006-12-15 EP EP06126282A patent/EP1932437A1/en not_active Ceased
-
2007
- 2007-12-10 US US12/519,043 patent/US9943097B2/en active Active
- 2007-12-10 MY MYPI20092367A patent/MY158502A/en unknown
- 2007-12-10 UA UAA200907388A patent/UA96781C2/en unknown
- 2007-12-10 BR BRPI0721087-6A patent/BRPI0721087A2/en not_active Application Discontinuation
- 2007-12-10 PL PL07857342T patent/PL2096941T3/en unknown
- 2007-12-10 EP EP07857342A patent/EP2096941B1/en active Active
- 2007-12-10 ES ES07857342T patent/ES2379737T3/en active Active
- 2007-12-10 CA CA002671988A patent/CA2671988A1/en not_active Abandoned
- 2007-12-10 CN CNA2007800487951A patent/CN101573049A/en active Pending
- 2007-12-10 RU RU2009127103/13A patent/RU2455857C2/en active
- 2007-12-10 AU AU2007331578A patent/AU2007331578B2/en active Active
- 2007-12-10 MX MX2009006086A patent/MX2009006086A/en active IP Right Grant
- 2007-12-10 WO PCT/EP2007/063622 patent/WO2008071667A1/en not_active Ceased
- 2007-12-10 PT PT07857342T patent/PT2096941E/en unknown
- 2007-12-10 AT AT07857342T patent/ATE543395T1/en active
- 2007-12-14 CL CL2007003650A patent/CL2007003650A1/en unknown
- 2007-12-14 TW TW096148143A patent/TW200845917A/en unknown
-
2009
- 2009-07-14 ZA ZA200904918A patent/ZA200904918B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124237A1 (en) * | 2001-12-21 | 2003-07-03 | Wyeth | Infant formula compositions comprising increased amounts of alpha-lactalbumin |
| WO2004112508A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
| WO2006057551A1 (en) * | 2004-11-26 | 2006-06-01 | N.V. Nutricia | Infant nutrition with protease inhibitor |
| WO2006069918A1 (en) * | 2004-12-27 | 2006-07-06 | Nestec S.A. | Use of infant formula with reduced protein content |
| WO2007004878A2 (en) * | 2005-07-01 | 2007-01-11 | N.V. Nutricia | Infant nutrition with hydrolised proteins |
Non-Patent Citations (2)
| Title |
|---|
| DEMMELMAIR H, VON ROSEN J, KOLETZKO B: "Long-term consequences of early nutrition", EARLY HUMAN DEVELOPMENT, vol. 82, no. 8, August 2006 (2006-08-01), pages 567 - 574, XP002429678 * |
| FOMON SJ, ZIEGLER EE, NELSON SE, FRANTZ JA: "What is the safe protein-energy ratio for infant formulas?", AMERICAL JOURNAL OF CLINICAL NUTRITION, vol. 62, 1995, pages 358 - 363, XP009082308 * |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703173B2 (en) | 2003-02-10 | 2014-04-22 | University College London | Newborn infant formulas and feeding methods |
| US8815279B2 (en) | 2003-02-10 | 2014-08-26 | University College London | Baby feeding formula and system |
| US7998501B2 (en) | 2003-02-10 | 2011-08-16 | University College London | Newborn infant formulas and feeding methods |
| WO2010070613A2 (en) | 2008-12-18 | 2010-06-24 | University College London | Baby feeding formula and system |
| WO2010070613A3 (en) * | 2008-12-18 | 2010-12-23 | University College London | Baby feeding formula and system |
| RU2559646C2 (en) * | 2009-04-01 | 2015-08-10 | Нестек С.А. | Adiposity risk reduction |
| US9480670B2 (en) | 2009-04-01 | 2016-11-01 | Nestec S.A. | Reduction of risk of obesity |
| WO2010112429A1 (en) * | 2009-04-01 | 2010-10-07 | Nestec S.A. | Reduction of risk of obesity |
| CN102368913A (en) * | 2009-04-01 | 2012-03-07 | 雀巢产品技术援助有限公司 | Reduction of risk of obesity |
| US9480671B2 (en) | 2009-04-01 | 2016-11-01 | Nestec S.A. | Reduction of risk of obesity |
| AU2010230362B2 (en) * | 2009-04-01 | 2015-01-15 | Société des Produits Nestlé S.A. | Reduction of risk of obesity |
| EP2277395A1 (en) * | 2009-07-23 | 2011-01-26 | Opus Ingredients B.V. | Composition, method for producing it and use thereof |
| US10548869B2 (en) | 2010-03-17 | 2020-02-04 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes |
| US11109603B2 (en) | 2011-06-20 | 2021-09-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
| US11771102B2 (en) | 2011-06-20 | 2023-10-03 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
| EP2583562A1 (en) | 2011-10-21 | 2013-04-24 | Nestec S.A. | Use of whey protein micelles for infants at risk of obesity or diabetes |
| WO2013057233A1 (en) | 2011-10-21 | 2013-04-25 | Nestec S.A. | Use of whey protein micelles for infants at risk of obesity or diabetes |
| EP2779846B1 (en) | 2011-10-21 | 2017-09-06 | Nestec S.A. | Use of whey protein micelles for infants at risk of obesity or diabetes |
| US9474766B2 (en) | 2011-12-27 | 2016-10-25 | Abbott Laboratories | Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life |
| US11376222B2 (en) | 2013-11-01 | 2022-07-05 | N.V. Nutricia | Lipid composition for improving body composition during catch-up growth |
| US20170000181A1 (en) * | 2013-11-29 | 2017-01-05 | Nestec S.A. | Age-tailored nutritional compositions with a varying protein content |
| WO2015078938A1 (en) | 2013-11-29 | 2015-06-04 | Nestec S.A. | Age-tailored nutritional compositions with a varying protein content |
| EP3082463B1 (en) | 2013-11-29 | 2019-05-01 | Nestec S.A. | Use of nutritional compositions having a low protein amount |
| EP3073844B1 (en) | 2013-11-29 | 2020-01-22 | Société des Produits Nestlé S.A. | Age-tailored nutritional compositions with a varying protein content |
| WO2017064304A1 (en) | 2015-10-15 | 2017-04-20 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| EP3574771A1 (en) | 2015-10-15 | 2019-12-04 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| US11389403B2 (en) | 2015-10-15 | 2022-07-19 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| EP4190174A1 (en) | 2015-10-15 | 2023-06-07 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| WO2017064309A1 (en) | 2015-10-15 | 2017-04-20 | N.V. Nutricia | Infant formula with milk fat for promoting healthy growth |
| EP3442358B1 (en) | 2016-04-11 | 2021-02-17 | Société des Produits Nestlé S.A. | Infant nutrition delivering metabolic benefits |
| US11388922B2 (en) | 2016-04-11 | 2022-07-19 | Societe Des Produits Nestle S.A. | Infant nutrition delivering metabolic benefits |
| US12004545B2 (en) | 2016-04-11 | 2024-06-11 | Societe Des Produits Nestle S.A. | Infant nutrition delivering metabolic benefits |
| EP3841892A1 (en) | 2016-05-10 | 2021-06-30 | N.V. Nutricia | Fermented infant formula |
| WO2017194615A1 (en) | 2016-05-10 | 2017-11-16 | N.V. Nutricia | Fermented infant formula |
| WO2017194607A1 (en) | 2016-05-10 | 2017-11-16 | N.V. Nutricia | Fermented infant formula |
| US11632974B2 (en) | 2016-12-09 | 2023-04-25 | N.V. Nutricia | Nutritional composition for improving cell membranes |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0721087A2 (en) | 2014-02-25 |
| EP2096941A1 (en) | 2009-09-09 |
| CL2007003650A1 (en) | 2009-03-27 |
| EP2096941B1 (en) | 2012-02-01 |
| US9943097B2 (en) | 2018-04-17 |
| MY158502A (en) | 2016-10-14 |
| PL2096941T3 (en) | 2012-07-31 |
| RU2009127103A (en) | 2011-01-20 |
| MX2009006086A (en) | 2009-07-02 |
| ES2379737T3 (en) | 2012-05-03 |
| TW200845917A (en) | 2008-12-01 |
| PT2096941E (en) | 2012-04-11 |
| EP1932437A1 (en) | 2008-06-18 |
| UA96781C2 (en) | 2011-12-12 |
| CA2671988A1 (en) | 2008-06-19 |
| AU2007331578A1 (en) | 2008-06-19 |
| CN101573049A (en) | 2009-11-04 |
| ATE543395T1 (en) | 2012-02-15 |
| RU2455857C2 (en) | 2012-07-20 |
| US20100092610A1 (en) | 2010-04-15 |
| ZA200904918B (en) | 2010-09-29 |
| AU2007331578B2 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007331578B2 (en) | Nutritional composition | |
| EP1220620B1 (en) | Composition comprising casein protein and whey protein | |
| WO2006069918A1 (en) | Use of infant formula with reduced protein content | |
| EP2413718B1 (en) | Use of arachidonic acid for the reduction of the risk of insulin resistance later in life | |
| AU2009306497B2 (en) | Nutritional composition with anti-regurgitation properties | |
| WO2019104390A1 (en) | Milk substitute compositions | |
| WO2010066569A1 (en) | Modulation of infant fat mass | |
| HK1122700A (en) | Infant formula | |
| MX2008009805A (en) | Nutritional composition for low birth weight infants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200780048795.1 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07857342 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007857342 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2671988 Country of ref document: CA Ref document number: 3771/DELNP/2009 Country of ref document: IN Ref document number: MX/A/2009/006086 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12519043 Country of ref document: US Ref document number: 2007331578 Country of ref document: AU |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12009501232 Country of ref document: PH |
|
| ENP | Entry into the national phase |
Ref document number: 2007331578 Country of ref document: AU Date of ref document: 20071210 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2009127103 Country of ref document: RU Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: PI0721087 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090615 |